TARA Protara Therapeutics
Price Chart
Executive Summary
Protara Therapeutics reported strong interim clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC), showing a 68% complete response rate at six months in BCG-Unresponsive patients, alongside Breakthrough Therapy and Fast Track designations for lymphatic malformations. The company raised $86.3 million in a public offering, extending its cash runway into 2028, despite increased R&D and G&A expenses leading to a wider net loss. No revenue was generated as the company remains pre-commercial.
Key Financial Metrics
Actionable Insight
Investors should monitor upcoming catalysts: regulatory update for LMs in 1H 2026, interim THRIVE-3 data in 2H 2026, and completion of BCG-Unresponsive cohort enrollment in ADVANCED-2. The strong clinical data and extended runway reduce near-term dilution risk and increase probability of regulatory success.
Key Facts
- TARA-002 demonstrated 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients (22 evaluable patients)
- Breakthrough Therapy and Fast Track designations received for TARA-002 in lymphatic malformations (LMs)
- Completed $86.3 million public offering, bringing cash, cash equivalents, and investments to $197.9 million as of December 31, 2025
- Cash runway now extends into 2028, funding key milestones including ADVANCED-2/3 and THRIVE-3 trials
- Net loss widened to $57.4 million in 2025 from $44.6 million in 2024 due to higher R&D and G&A spending
- No revenue reported — company remains clinical-stage with no commercial products
Financial Impact
Increased annual net loss by $12.8 million to $57.4M; raised $86.3M in gross proceeds, boosting cash reserves by ~120%
Risk Factors
- Clinical-stage biotech with no revenue; valuation dependent on trial outcomes
- Widening losses reflect advancing trials, but long-term profitability remains uncertain
- Market volatility could impact ability to raise capital if runway needs extension
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252699 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
20d ago
|
EFFECT
| $4.80 $4.34 | ▲ +9.58% | ▲ +10.80% | $3.90 (+18.75%) |
|
May 16, 2026
29d ago
|
ANALYST-UPGRADE
| $6.20 $5.60 | ▼ −9.68% | ▼ −8.34% | $3.90 (−37.10%) |
|
May 15, 2026
4w ago
|
Press Release
| $5.10 $4.92 | ▼ −3.53% | ▼ −4.49% | $3.90 (−23.53%) |
|
May 13, 2026
4w ago
|
8-K
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
May 13, 2026
4w ago
|
Press Release
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $5.17 $5.66 | ▲ +9.48% | ▲ +6.37% | $3.90 (−24.56%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access